Elekta AB Unsponsored American Depositary Receipt (EKTAY)
OTC PINK OTC PINK Primary 
XMUN 
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
Elekta AB: Tricky, But With A Latent Upside
Elekta AB (publ) is rated Buy with a 56 SEK ($6 ADR) price target, reflecting a 15% annualized return potential at 15x P/E. EKTAY's historical premium is no longer justified due to persistent earnings misses, slow growth, and margin challenges, but current valuation now offers upside. Recent improvements include a 300 bps EBIT margin rise, 4.3% yield with a 79% payout ratio, and positive book-to-bill and cash flow trends.
Elekta AB (publ) (EKTAY) Q3 2026 Earnings Call Transcript
Elekta AB (publ) (EKTAY) Q3 2026 Earnings Call Transcript
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology
EKTAY jumps after FDA clears Evo CT-Linac, opening U.S. access to AI-driven CT imaging that boosts precision and efficiency in radiation therapy.
Elekta AB (publ) (EKTAY) Q2 2026 Earnings Call Transcript
Elekta AB (publ) (OTCPK:EKTAY) Q2 2026 Earnings Call November 26, 2025 4:00 AM EST Company Participants Peter Nyquist - Head of Investor Relations Jakob Just-Bomholt - CEO & President Tobias Hagglov - Chief Financial Officer Conference Call Participants Kavya Deshpande - UBS Investment Bank, Research Division Mattias Vadsten - SEB, Research Division Kristofer Liljeberg-Svensson - DNB Carnegie, Research Division Ludwig Germunder - Handelsbanken Capital Markets AB, Research Division Erik Cassel - Danske Bank A/S, Research Division Veronika Dubajova - Citigroup Inc., Research Division Jonathon Unwin - Barclays Bank PLC, Research Division Sten Gustafsson - ABG Sundal Collier Holding ASA, Research Division David Adlington - JPMorgan Chase & Co, Research Division Ludvig Lundgren - Nordea Markets, Research Division Presentation Peter Nyquist Head of Investor Relations Hi, and good morning, everyone, and welcome to this second quarter Investor and Analyst Call. My name is Peter Nyquist.
Elekta AB: Latent Growth And A Recurring Base
Elekta operates in a secularly growing cancer radiotherapy market, with strong long-term demand drivers, especially in emerging markets. The company boasts solid free cash flow yield and a growing recurring revenue base, supported by service contracts that lift earnings and offer downside protection. Recent product launches, especially Elekta Evo, are driving a turnaround in sales and EBITDA growth.
Should Value Investors Buy Elekta (EKTAY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Elekta (EKTAY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Elekta (EKTAY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Elekta (EKTAY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Elekta (EKTAY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
